Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27536969 | 0.76 | ALDH1A1 (0.72) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL2226978 | 0.75 | ALDH1A1 (0.55) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL4079229 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL27741699 | 0.74 | ALDH1A1 (0.80) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL868588 | 0.74 | ALDH1A1 (0.61) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL14001694 | 0.73 | ALDH1A1 (1.00) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL111407 | 0.73 | ALDH1A1 (1.00) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL19924617 | 0.73 | ALDH1A1 (1.00) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL8607770 | 0.73 | ALDH1A1 (1.00) | ALDH1A1TDP1POLBNPSR1LMNA | |
| SCHEMBL4115035 | 0.73 | ALDH1A1 (0.56) | ALDH1A1TDP1POLBNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2007134449-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | ALDH1A1 4135/4885TDP1 1634/4885POLB 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.